Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Insulet Corporation

In a report released today, Richard Newitter from Truist Financial reiterated a Buy rating on Insulet, with a price target of $412.00. Newitter cov...

Insulet (PODD) Gets a Buy from Truist Financial

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Insulet yesterday and set a price target of $380.00. The company’s shares closed...

RBC Capital Remains a Buy on Insulet (PODD)

In a report released today, Jonathan Block from Stifel Nicolaus maintained a Buy rating on Insulet, with a price target of $370.00. Block covers th...

Stifel Nicolaus Sticks to Its Buy Rating for Insulet (PODD)

Barclays analyst Matt Miksic maintained a Hold rating on Insulet today and set a price target of $301.00. The company’s shares closed yesterday at ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PODD	$331.17	+5.84%	1.44M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PODD	$331.17	+5.8%	1.44M
3
4
5
6

PODD

PODD

No Data Available

Get Insulet Corporation Data in Excel

Get Insulet Corporation Data in Excel